Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

At-Risk Launches: Three Cases May Determine How Damages Are Calculated

23 May 2011

• By Brenda Sandburg

How risky are at-risk launches of generic products?

Related Content

Anatomy Of A Patent Dispute: Purdue Pharma’s OxyContin Battle

10 Mar 2008

At-Risk Abundance: Generic Launch Gambles Usually Pay Off

23 May 2011

Patent Fights In Brief: AstraZeneca And Wyeth Face Challenges

20 Apr 2009

Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix

26 Apr 2010

Famvir Patent Settlement: 17 Months After At-Risk Launch, Teva Must Pay Novartis

16 Feb 2010

Apotex To Retain About $300 Million From Its At-Risk Launch of Generic Plavix

20 Oct 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.